Inventiva Secures $120M Equity Offering and €130M Debt Financing, Restructures EIB Debt to Extend Runway
Summary
Inventiva announced a comprehensive refinancing package, including a $120 million equity offering, up to €130 million in new debt, and a restructuring of its EIB loan and warrants, to address financial distress and extend its cash runway.
Key Events
-
$120M Equity Offering Priced
The company issued 27,272,727 American Depositary Shares (ADSs) at $4.40 per ADS, a 9.5% discount to the Euronext volume-weighted average price (VWAP), raising approximately $110.8 million in net proceeds. This finalizes the pricing of an offering initiated on 2026-06-02.
-
€130M Debt Financing Secured
Inventiva secured a new debt financing facility of up to €130 million in committed tranches (plus an uncommitted €20 million) from BlackRock and Claret Capital Partners, with an initial aggregate drawdown of €75 million. This extends the company's debt maturity profile to 2030.
-
EIB Debt and Warrants Restructured
The company will repay its existing European Investment Bank (EIB) loan (approximately €63 million outstanding) and repurchase 22.7 million EIB warrants for €50 million, representing a 40% discount to their intrinsic value. The remaining 15.7 million EIB warrants will be substituted with new ones that do not contain anti-dilution provisions, subject to shareholder approval.
-
Extended Financial Runway
The combined transactions are expected to extend Inventiva's cash runway into early Q1 2028, contingent on the full drawdown of Tranche C of the new debt and the exercise of T3 warrants.
Analysis
Inventiva, facing significant financial challenges including a 'going concern' warning and low shareholders' equity, has secured a comprehensive refinancing package. This transaction provides a substantial capital infusion through a $120 million equity offering and up to €130 million in new debt, crucial for extending its operational runway into early 2028. The restructuring of existing EIB debt and warrants also simplifies the capital structure and mitigates future dilution risks. While the equity offering is dilutive and the debt carries high interest rates, this financing is essential for the company to continue its pivotal Phase 3 clinical trial for lanifibranor and address its immediate liquidity needs.
At the time of this filing, IVA was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $833.3M. The 52-week trading range was $2.85 to $7.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.